This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Shoenfeld, Y. Articles by Blank, M. Search for Related Content PubMed PubMed Citation Articles by Shoenfeld, Y. Articles by Blank, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

Effect of Long-Acting Thromboxane Receptor Antagonist (BMS 180,291) on Experimental Antiphospholipid Syndrome

Research Unit of Autoimmune Diseases, Department of Medicine B, Sheba Medical Center Tel-Hashomer 52621, Sackler Faculty of Medicine Tel-Aviv University, Israel

Miri Blank

, Research Unit of Autoimmune Diseases, Department of Medicine B, Sheba Medical Center Tel-Hashomer 52621, Sackler Faculty of Medicine Tel-Aviv University, Israel

Antiphospholipid syndrome (APS) is characterized by recurrent thromboembolic phenomena, recurrent fetal loss and thrombocytopenia associated with high titers of IgG anticardiolipin antibodies and/or lupus anticoagulant. There is an increased platelet aggregation in these patients and thus aspirin was found to be effective in abrogating some of the clinical findings.

The purpose of this study was to employ the experimentally induced APS in mice infused with anticardiolipin antibodies, to study the effect of a thromboxane receptor antagonist (BMS, 180, 291) on the various overt manifestations of APS.

Experimental APS was induced in pregnant female mice by iv infusion of a pathogenic anticardiolipin antibody (CAM). The mice were then treated daily with 300 µg/mouse of BMS. The study group and the untreated group were killed on day 17 of pregnancy. Live and absorbed fetuses and the mean weight of the placentae, fetuses and platelet counts were recorded.

BMS treated mice had a significant reduction in fetal resorption rate from 45% to 19.8% and an increase in mean placental and embryo weights (182 vs 104, 1043 vs 721 mg, respectively). In parallel, an increase in platelet count (from 597 100 to 1075 000 platelets/mm ³) and decrease in activated thromboplastin time (95 to 44 s) was seen.

It seems that thromboxane receptor antagonist may be effective in abrogating the diverse manifestations seen in APLS. Increased platelet aggregation may be one of the pathogenetic mechanisms in APS.

Key Words: Antiphospholipid syndrome • Platelet aggregation • Thromboxane

Lupus, Vol. 3, No. 5, 397-400 (1994)
DOI: 10.1177/096120339400300506


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y Shoenfeld Systemic antiphospholipid syndrome Lupus, July 1, 2003; 12(7): 497 - 498. [Abstract] [PDF]

				M. Hojnik, J. George, L. Ziporen, and Y. Shoenfeld Heart Valve Involvement (Libman-Sacks Endocarditis) in the Antiphospholipid Syndrome Circulation, April 15, 1996; 93(8): 1579 - 1587. [Abstract] [Full Text]

				M. D. Lockshin Answers to the Antiphospholipid-Antibody Syndrome? N. Engl. J. Med., April 13, 1995; 332(15): 1025 - 1027. [Full Text]

				Y. Shoenfeld, M. Blank, and P. Fishman Antiphospholipid syndrome: from the laboratory bench to the patients' bedside Lupus, July 1, 1994; 4(1_suppl): S33 - S36. [PDF]